Petros PharmaceuticalsPTPI -12.07% EBIT per Share is $-0.12 as of Mar. 2026. Among 810 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 97.9% on this metric.
Petros Pharmaceuticals's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.12.
During the past 3 years, the average EBIT per Share Growth Rate was 90.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 78.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Petros Pharmaceuticals's EBIT per Share or its related term are showing as below:
PTPI'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 23.9 Med: 57 Max: 90.5
Current: 90.5
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Petros Pharmaceuticals was 90.50% per year. The lowest was 23.90% per year. And the median was 57.00% per year.
PTPI's 3-Year EBIT Growth Rate is ranked better than 97.9% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs PTPI: 90.50
Petros Pharmaceuticals (OTCPK:PTPI) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Petros Pharmaceuticals EBIT per Share Related Terms
Petros Pharmaceuticals EBIT per Share Historical Data
* Premium members only.
The historical data trend for Petros Pharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (PTPI) has a EBIT per Share of $-0.12 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Petros Pharmaceuticals and its competitors. According to the industry distribution chart, Petros Pharmaceuticals ranks #17 out of 810 companies in the Drug Manufacturers industry, placing it in the top 2.1%.
Is Petros Pharmaceuticals' EBIT per Share too high?
Petros Pharmaceuticals' current EBIT per Share is $-0.12. Based on the distribution chart, Petros Pharmaceuticals ranks #17 out of 810 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Petros Pharmaceuticals' EBIT per Share compare to STEK and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #17 out of 810 companies for EBIT per Share. This places Petros Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current EBIT per Share is $-0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current EBIT per Share of $-0.12. The current EBIT per Share is $-0.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current EBIT per Share is $-0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 